208 related articles for article (PubMed ID: 31332495)
1. Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2223-2224. PubMed ID: 31332495
[TBL] [Abstract][Full Text] [Related]
2. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Hicks RJ; Hindié E; Guillet BA; Avram A; Ghedini P; Timmers HJ; Scott AT; Elojeimy S; Rubello D; Virgolini IJ; Fanti S; Balogova S; Pandit-Taskar N; Pacak K
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2112-2137. PubMed ID: 31254038
[TBL] [Abstract][Full Text] [Related]
3. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.
Taïeb D; Timmers HJ; Hindié E; Guillet BA; Neumann HP; Walz MK; Opocher G; de Herder WW; Boedeker CC; de Krijger RR; Chiti A; Al-Nahhas A; Pacak K; Rubello D;
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1977-95. PubMed ID: 22926712
[TBL] [Abstract][Full Text] [Related]
4. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
Ryder SJ; Love AJ; Duncan EL; Pattison DA
Clin Endocrinol (Oxf); 2021 Jul; 95(1):13-28. PubMed ID: 33296100
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian look at the new 2019 guidelines for imaging of pheochromocytoma/paraganglioma with emphasis on extra-adrenal disease.
Ilias I; Meristoudis G
Hell J Nucl Med; 2019; 22(2):142. PubMed ID: 31273358
[TBL] [Abstract][Full Text] [Related]
6. Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes.
Taïeb D; Pacak K
J Nucl Med; 2020 May; 61(5):643-645. PubMed ID: 32198315
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
8. Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.
Cuccurullo V; Mansi L
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1262-5. PubMed ID: 22644715
[No Abstract] [Full Text] [Related]
9. Functional imaging for pheochromocytoma-paraganglioma: a step closer to understanding its place in clinical practice.
Jimenez C; Waguespack SG
Endocrine; 2015 Sep; 50(1):6-8. PubMed ID: 26113425
[No Abstract] [Full Text] [Related]
10. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs.
Zukauskaite R; Hjorthgau K; Poulsen PL; Baerentzen S; Ladekarl M
Acta Oncol; 2011 Nov; 50(8):1255-9. PubMed ID: 21714698
[No Abstract] [Full Text] [Related]
11. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
12. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma and Paraganglioma in Pregnancy: a New Era.
Gruber LM; Young WF; Bancos I
Curr Cardiol Rep; 2021 May; 23(6):60. PubMed ID: 33961120
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
16. Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine.
Taïeb D; Fargette C; Jha A; Pacak K
Endocr Relat Cancer; 2023 Apr; 30(4):. PubMed ID: 36633962
[TBL] [Abstract][Full Text] [Related]
17. Addressing delays in the diagnosis of pheochromocytoma/paraganglioma.
Ilias I; Thomopoulos C
Expert Rev Endocrinol Metab; 2019 Sep; 14(5):359-363. PubMed ID: 31429343
[No Abstract] [Full Text] [Related]
18. Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.
Björklund P; Pacak K; Crona J
J Intern Med; 2016 Dec; 280(6):559-573. PubMed ID: 27165774
[TBL] [Abstract][Full Text] [Related]
19. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
Crona J; Taïeb D; Pacak K
Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
[TBL] [Abstract][Full Text] [Related]
20.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
